TEREOTACTIC or neuronavigated biopsies are frequently performed to achieve a histological diagnosis in patients with intracerebral lesions that are supposed to be diffuse gliomas on MR imaging. 15, 33 Given that the procedure morbidity rates range from 1 to 4.7% and those for mortality from 0 to 2.3%, 1, 12, 29, 46 ,61 efforts should be undertaken to optimize the diagnostic yield of such biopsies. Because of the pronounced regional heterogeneity of many glial tumors, the accuracy of the histopathological classification and tumor grading strongly depends on the selected biopsy site.
Because of the uncertainties in using MR imaging for an accurate noninvasive assessment of brain lesions, 48, 57 several attempts have been made to apply novel imaging techniques. In addition to CT and MR studies, metabolic imaging with PET, MR spectroscopy, and MR spectroscopic imaging have been considered. Both MR spectroscopy and MR spectroscopic imaging are able to detect the concentration of various metabolites within brain tissue and provide a noninvasive means of monitoring biological and metabolic parameters of gliomas. 10, 13, 26, 32, 38, 40, 41, 49, 50, 55, 56 Vital glioma tissue is usually characterized by an elevated-to-high concentration of the cell membrane marker Cho and its metabolites, indicating cellular proliferation, and a decreased concentration or the absence of NAA, denoting loss of neurons as they are replaced by tumor cells. A threshold NAA/Cho ratio of 0.7 or less is accepted as indicative of a neoplastic lesion. 42 Radiolabeled amino acids have been shown to be useful tracers for tumor diagnostics in neurooncological analyses. 22, 30 Positron emission tomography with MET or L- [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] C]tyrosine has been used in many studies. 3, [6] [7] [8] [9] 21, 28, 43, 53, 54 Given the short-lived 11 C label (20-minute half-life), however, these tracers remain restricted to only a few PET centers with a cyclotron on site. Recently, 18 F-labeled amino acids such as FET have been developed and can be synthesized with high radiochemical yields, thus allowing large-scale production for clinical purposes. 17, 60 Initial clinical studies in which researchers performed FET-PET in humans with brain tumors have shown results similar to those obtained using MET-PET. 47, 59 A superior delineation of the cellular glioma mass in humans has been demonstrated by FET-PET compared with MR imaging; stereotactic biopsies were performed as reference. 39 Furthermore, results of animal experiments have shown that FET, in contrast to MET and FDG, exhibits low uptake in nonneoplastic and inflammatory cells, a finding that promises a high specificity for the in vivo detection of tumor cells. 24, 52 To evaluate the use of single-voxel MR spectroscopy and FET-PET for the noninvasive identification of brain tumors and the selection of diagnostically meaningful biopsy sites, we conducted a prospective study in 50 patients harboring intracerebral lesions suspected to be diffuse gliomas based on MR images. In all patients, neuronavigated tissue biopsy specimens were obtained and the histological findings were compared with corresponding data gleaned from MR imaging, MR spectroscopy, and FET-PET studies.
Clinical Material and Methods

Patient Population
Between September 2001 and December 2003, MR imaging and FET-PET investigations with subsequent biopsies were conducted in 91 patients in whom intracerebral lesions had been newly diagnosed based on MR imaging results. Glioma was the first differential diagnosis in all patients. In 50 of these patients, MR spectroscopy was additionally performed. These 50 included 29 female and 21 male patients (mean age 44.3 years, range 2-74 years) and they all underwent a standard set of preoperative investigations: 1) enhanced MR imaging; 2) PET with the amino acid FET; and 3) single-voxel proton MR spectroscopy. The entire preoperative imaging process was undertaken within a maximum of 2 weeks before biopsy.
Initial symptoms consisted of seizures in 33 patients, whereas focal neurological deficits and/or increased intracranial pressure symptoms were the leading signs in 17. In four patients with intracranial hypertension, hydrocephalus was the main sign (Cases 8 and 23, bilateral thalamic lesions; Case 7, bilateral hypothalamic lesion; and Case 36, multiple brainstem lesions). Twenty-one patients presented with space-occupying lesions causing mass effect (ventricular compression and midline shift) and 29 patients had lesions without significant mass effect. The lesion locations were as follows: 47 patients had supratentorial lesions, with 36 lobar and 11 deep-seated locations. There were 24 left hemispheric, 15 right hemispheric, and eight bihemispheric lesions. Three tumors were located in the posterior fossa. The lesions were unifocal in 41 patients and multifocal in nine. Detailed information about the individual patients is featured in Table 1 .
This study was approved by the local institutional review board at the Medical Faculty of Heinrich-Heine-University and federal authorities. All patients gave written informed consent for participation in the study.
Magnetic Resonance Imaging
The MR imaging examinations were performed on a 1.5-tesla system (Sonata; Siemens, Erlangen, Germany). The conventional imaging protocol consisted of a T 1 -weighted 3D-MPRAGE sequence (field of view 25 cm, matrix 205 ϫ 256, TR 2200 msec, TE 3.9 msec, TI 1200 msec, flip angle 15, number of slices 128, slice thickness 1.5 mm, slice gap 0 mm, number of averages 1, and time of acquisition 6:38 min) before and 2 minutes after injection of 20 ml Gd-DTPA (Magnevist; Schering, Germany) and a transversal FLAIR sequence (field of view 25 cm, matrix 205 ϫ 256, TR 9000 msec, TE 119 msec, TI 2500 msec, flip angle 90, number of slices 25, slice thickness 5 mm, slice gap 0 mm, number of averages 2, and time of acquisition 4:32 min).
Positron Emission Tomography With FET
The amino acid FET was produced via phase transfermediated nucleophilic 18 F-fluorination of N-trityl-O-(2-tosyloxyethyl)-L-tyrosine tert-butyl ester and subsequent deprotection with a specific radioactivity of greater than 200 GBq/mol by optimizing the previous method. 17 The uncorrected radiochemical yield was approximately 35% and the radiochemical purity was greater than 98%. The tracer was administered as an isotonic neutral solution. The PET studies were acquired 15 to 40 minutes after intravenous injection of 200 MBq FET. The measurements were performed on an ECAT EXACT HR+ unit in 3D mode (32 rings Ge markers were used as fiducials.
Magnetic Resonance Spectroscopy
The 1 H spectroscopic measurements were performed on a clinical whole-body MR system (Magnetom Vision Plus; Siemens) at a field strength of 1.5 tesla by using the circular polarized standard head coil with the point-resolved spectroscopy double-spin echo localization sequence. 2 Spectra were obtained at TE 135 msec and TR 1500 msec by using 
* All patients demonstrated increased signal on T 2 -weighted FLAIR sequences. Abbreviations: A = diffuse astrocytoma; AA = anaplastic astrocytoma; AO = anaplastic oligodendroglioma; AOA = anaplastic oligoastrocytoma; bi = bihemispheric lesion; E = ependymoma; Fr = frontal; L/B = lesion-to-healthy brain tissue; O = occipital; OA = olioastrocytoma; OG = oligodendroglioma; P = parietal; PA = pilocytic astrocytoma; PE = number of distinct areas subjected to neuronavigated biopsy; T = temporal; ϩ = presence of a clinical sign (seizure, deficit, or mass effect) or a positive result on imaging; -= absence of a sign or a negative result on imaging.
† Patient presented with seizures as the initial symptom. ‡ Neurological deficits or symptoms of increased intracranial pressure as initial signs. § Lesion was space occupying with ventricular compression/midline shift. || Gadolinium enhancement within the lesion on MR images. 128 averages to get acceptable signal/noise ratios. The size of the target volumes ranged from 8 to 20 ml, adapted to the individual tumor lesions. The spectra were evaluated through simple peak integration after increasing the line width by approximately 2 Hz by using commercially available software, which analyzes the spectra as a linear combination of different model spectra and has proven to be very useful in analyzing in vivo MR spectra of human brain. 51 The following spectral resonances were assigned to the different metabolites: Cho at 3.2 ppm, creatine/phosphocreatine at 3 ppm, NAA at 2 ppm, and lactate at 1.3 ppm.
Neuronavigated Biopsy Procedure
Positron emission tomography images were coregistered with MR images by using dedicated software (MPI tool 3.28; ATV, Cologne, Germany), and PET and MR imaging data were then incorporated into the neuronavigation system. For coregistration, anatomical landmarks and external cutaneous fiducial markers were used in each examination. The MR spectroscopy data were not used to determine the biopsy sites. Areas with increased signal intensities on T 2 -weighted FLAIR sequences and increased uptake of FET on PET images exceeding the mean of normal brain tissue by three standard deviations were determined by computerized analysis. On this basis, FET-PET/MR imaging matched and mismatched areas were identified for targeted biopsies. For lesions with increased FET uptake (Fig. 1A) , biopsy specimens were obtained from areas with both abnormal MR signal (FLAIR hyperintensity) and increased FET uptake (match biopsy; Fig. 1D ) and from areas with abnormal MR signal but no increased FET uptake (mismatch biopsy). For lesions without increased FET uptake ( Fig. 2A) , biopsy specimens were taken from areas with abnormal MR signal only (Fig. 2D) . For large lesions and those in easily amenable areas, usually two or three biopsy sites were selected; for small lesions or those in eloquent areas, usually only one biopsy site was chosen. In patients with multiple distinct FET-positive lesions, the site with the greatest FET uptake was selected for tissue sampling (examples and figures for bilateral and multifocal lesions). 39 In patients with multiple FET-negative lesions, the site with the lowest surgical risk was selected for biopsy.
The tumors were sampled with the aid of a standard stereotactic biopsy cannula, which was referenced to the neuronavigation system and connected to an adjustable Leyla arm. Through a small skin incision and a standard 8-mm burr hole, the cannula was placed into the area of interest by using neuronavigational control. A 2-mm stereotactic forceps was manipulated to obtain at least five and at most 12 biopsy specimens. Selected biopsy sites were labeled with intracerebral titanium pellets, allowing exact documentation of the biopsy sites on postoperative imaging.
Histopathological Studies
The histological assessment was performed on tissue sections of each biopsy specimen after formalin fixation and paraffin embedding. The histological diagnoses were determined by an experienced neuropathologist (G.R.) according to the WHO classification of tumors of the central nervous system. 
Statistical Analysis
Results of all MR imaging examinations were evaluated qualitatively by two neurosurgeons in consensus. The MR images were studied for 1) the presence and location of lesions demonstrating increased signal on T 2 -weighted FLAIR sequences; 2) for Gd enhancement on T 1 -weighted images after Gd-DTPA administration; and 3) for the location of increased FET uptake in relation to the location of increased signal on T 2 -weighted FLAIR sequences. Tumor/ brain tissue ratios of FET uptake were calculated by dividing the mean region-of-interest value of the lesion by that of healthy brain tissue in the contralateral hemisphere. A tumor/brain tissue ratio of 1.6 or more was considered positive. Magnetic resonance spectroscopy results were considered positive and indicative of neoplastic tissue by 1) a decreased concentration or absence of NAA; 2) an elevatedto-high concentration of Cho; and 3) an NAA/Cho ratio of 0.7 or less. A decrease of NAA alone, without increase of the absolute Cho concentration or the presence of a significant lactate peak, was classified as a negative MR spectroscopy result.
For a comparison of the FET lesion/brain ratio, the NAA/ Cho ratio, and signal abnormalities on MR images between tumor tissue and nonneoplastic tissue, we used the nonparametric Mann-Whitney U-test. For a comparison of the FET lesion/brain ratio and the NAA/Cho ratio together with the WHO grade, the Kruskal-Wallis test was used. Binary logistic regression analysis was performed to determine the diagnostic value of FET-PET and MR spectroscopy compared with conventional MR imaging in differentiating tumor tissue and nonneoplastic tissue. Binary logistic regression with a foreward conditional stepwise method was used (greatest likelihood method). All data analyses were performed using a commercially available software (Statistical Package for Social Sciences, version 11.0; SPSS, Inc., Chicago, IL). All statistical tests were considered significant at a probability level of less than 0.05.
Results
Histological investigation of the biopsy specimens revealed neoplastic lesions in 34 of 50 patients. These tumors included five GBMs WHO Grade IV, six anaplastic astrocytomas WHO Grade III, seven anaplastic oligoastrocytomas WHO Grade III, one anaplastic oligodendroglioma WHO Grade III, one oligoastrocytoma WHO Grade II, one oligodendroglioma WHO Grade II, 10 diffuse astrocytomas WHO Grade II, one ependymoma WHO Grade II, and two pilocytic astrocytomas WHO Grade I. In 16 patients, nonneoplastic lesions were diagnosed, including two instances of demyelinating disease, four ischemic infarcts, and 10 diagnostically nonspecific lesions characterized by edema, reactive astrogliosis, and microglial activation.
The exact biopsy site could be confirmed by postoperative imaging in all cases. Each biopsy sample was taken from within the selected area. Considering the relationship between the planned target point (defined as the middle of the selected biopsy track) and the true biopsy point (defined by the location of the titanium pellet), the titanium pellets were placed within 0 to 3 mm of the anticipated target point in 47 patients (94%); in three patients (6%) the distance was 4 to 6 mm. There was no case of procedure-related or perioperative death. One patient (Case 42) with a parietal lesion suffered from a significant postoperative hemorrhage and permanent hemiplegia despite immediate successful evacuation of the clot. Thus, the biopsy-related major morbidity rate in the present study was 2%. Minor morbidity, such as wound infection, meningitis, or seizures, was not observed. The location of the MR spectroscopy voxels is also demonstrated. F: An MR spectroscopic scan of the left frontal lesion demonstrating no significant difference from the contralateral healthy brain tissue (E). The NAA/Cho ratio was 0.9. G: Photomicrograph revealing white matter tissue with reactive astrogliosis, edema, and some microglial activation on CD68 immunostains (not shown). Tumor cells, inflammatory infiltrates, and demyelination were absent.
Magnetic Resonance Imaging Data
The intracerebral lesions exhibited increased signal intensity on T 2 -weighted FLAIR sequences in all 50 patients; that is, gliomas could not be reliably distinguished from nonneoplastic lesions on the FLAIR sequences. Lesions in 20 patients, including the 15 with a biopsy-proven tumor diagnosis, showed Gd enhancement on MR images. Gadolinium enhancement was demonstrated in five of five GBMs Grade IV, one of six anaplastic astrocytomas Grade III, three of seven anaplastic oligoastrocytomas Grade III, one of one anaplastic oligodendroglioma Grade III, one of one oligoastrocytoma Grade II, one of one oligodendroglioma Grade II, two of 10 diffuse astrocytomas Grade II, and one of two pilocytic astrocytomas Grade I. Five lesions with Gd enhancement corresponded to nonneoplastic lesions, that is, one demyelinating disease (Case 31), three ischemic infarcts (Cases 37, 48, and 49), and one nonspecific/reactive lesion (Case 39). When enhancement of Gd on T 1 -weighted MR sequences was considered as a parameter for the distinction between neoplastic and nonneoplastic lesions, the sensitivity was 44% and specificity 69%.
Magnetic Resonance Spectroscopy Data
The mean NAA/Cho ratio for the investigated gliomas (34 lesions) was 0.36 Ϯ 0.16, whereas the mean NAA/Cho ratio for the other lesions (16 lesions) was 0.99 Ϯ 0.58 (p Ͻ 0.001). According to results of MR spectroscopy, 37 of 50 lesions were considered neoplastic and 13 lesions nonneoplastic. All (34 of 34 lesions) histologically confirmed tumors demonstrated a positive MR spectroscopy result; among the 16 nonneoplastic brain lesions, MR spectroscopy represented 13 lesions correctly but rendered three falsepositive results (two demyelinating and one ischemic lesion). The sensitivity of MR spectroscopy was 100% and specificity 81%. The Kruskal-Wallis analysis showed no significant difference (p = 0.157) in the comparison of the NAA/Cho ratio with the histological WHO grading.
Results of FET-PET
The mean lesion/brain tissue ratio of FET uptake was 2.4 Ϯ 0.9 for the tumors (34 lesions) and thus was significantly higher compared with the lesion/brain tissue ratio of 1.2 Ϯ 0.4 for the nonneoplastic lesions (16 lesions; p Ͻ 0.001). The correlation of the lesion/brain tissue ratio with WHO grading demonstrated a trend toward higher FET lesion/brain tissue ratios for WHO Grades III and IV tumors, although a substantial overlap of the data was recognized and the differences were not significant (p = 0.097).
Thirty of the 34 gliomas demonstrated an increased FET uptake (lesion/brain tissue ratio Ն 1.6), whereas four gliomas (one anaplastic oligoastrocytoma Grade III, two diffuse astrocytomas Grade II, and one pilocytic astrocytoma Grade I) revealed normal FET metabolism (lesion/brain tissue ratio Ͻ 1.6). Among the 16 nonneoplastic brain tumors, 14 had normal FET uptake, whereas two lesions (one demyelinating disease and one reactive lesion) demonstrated a false-positive result with moderately increased FET uptake. The sensitivity and specificity of FET uptake for the distinction of tumors from nonneoplastic tissues was 88% and 88%, respectively.
In all FET-PET-positive gliomas of WHO Grade I, II, or III (29 lesions), the area of increased FET uptake was smaller than and located within the area of MR imaging signal abnormality (FLAIR hyperintensity; Fig. 1A and B) . In two of five patients with a GBM Grade IV, FET uptake was not restricted to the Gd-enhancing area but exceeded also the MR signal abnormality on T 2 -weighted FLAIR sequences for more than 10 mm. All 14 tumors with Gd enhancement were positive on FET-PET. In contrast, only one of the five nonneoplastic lesions with Gd enhancement was positive on FET-PET.
Combined Metabolic Imaging With FET-PET and MR Spectroscopy
Both FET-PET and MR spectroscopy were positive in the lesions of 31 patients (Cases 1-31 ). With only a single exception (Case 31), all these patients were histologically proven to harbor glial tumors (97%). The patient in Case 31 had a single large frontal lesion with ring enhancement on MR imaging and positivity on FET-PET and MR spectroscopy. Histological data revealed an inflammatory, actively demyelinating lesion with massive invasion of macrophages in this particular case.
Note that FET-PET was positive but MR spectroscopy negative in one patient with multifocal and bilateral lesions on MR imaging (Case 32). Neuronavigated biopsy specimens were taken from two of three distinct lesions with significant FET uptake. Histological analyses of both sites showed only nonspecific changes with cerebral edema, astrogliosis, and microglial activation but no diagnostic tumor tissue. Follow-up MR imaging was performed, and 15 months later the patient was found to have a histologically proven GBM exactly at one of the three sites with increased FET uptake, whereas the other two sites remained unchanged. Although results of FET-PET were negative, those of MR spectroscopy were positive in six patients (Cases 33-38). In four of them, histological investigation of the tissue specimens confirmed glial tumors (one anaplastic oligoastrocytoma Grade III, two diffuse astrocytomas Grade II, and one pilocytic astrocytoma Grade I). The remaining two patients were suffering from an ischemic infarct and a demyelinating disease, respectively.
Both FET-PET and MR spectroscopy were negative in 12 patients. Histological data did not reveal a tumor diagnosis in any of these patients. In three instances, histological results showed ischemic infarction, in nine instances nonspecific reactive lesions with edema, astrogliosis, and microglial activation. None of the latter nine patients had a tumor during a follow-up period of 9 to 29 months.
In the binary logistic regression analysis, the lesion/brain tissue ratio of the FET uptake and the NAA/Cho ratio were identified as significant independent predictors for the identification of gliomas. The accuracy for the distinction of gliomas and nonneoplastic lesions in our selected series of patients could be increased from 68% for MR imaging alone to 97% when MR imaging was combined with a positive result on both FET-PET and MR spectroscopy. The significant variables of this logistic regression model are featured in Table 2 .
Discussion
The goal of this study was to determine whether MR imaging combined with MR spectroscopy, and FET-PET is superior to MR imaging alone in predicting a definite histological tumor diagnosis on biopsy of newly diagnosed brain lesions. Therefore, we prospectively examined 50 patients with newly diagnosed intracerebral lesions with the aid of MR imaging, MR spectroscopy, and FET-PET. All lesions were then subject to a neuronavigational biopsy procedure with subsequent placement of titanium pellets for the postoperative documentation of the biopsy site. Precise labeling of the biopsy site is particularly important in those instances in which a definite histological diagnosis cannot be established. Our results demonstrated that the accuracy for the preoperative distinction of gliomas from nonneoplastic lesions can be increased from 68% with MR imaging alone to 97% when MR imaging was combined with metabolic imaging techniques of MR spectroscopy and FET-PET. For lesions that were positive on both MR spectroscopy and FET-PET studies, a tumor diagnosis was histologically verified in 97% of the cases. In one exceptional patient with ring enhancement on MR images, increased FET uptake, and a reduced NAA/Cho ratio, an actively demyelinating process was histologically diagnosed. Similar cases of demyelinating lesions mimicking malignant gliomas have been previously reported. 19 When FET-PET and MR spectroscopy were both negative, histological data always showed nonneoplastic disease.
Our study data confirm the common knowledge that signal abnormalities on MR images-including Gd enhancement-are not reliable predictors for the diagnosis and grading of glial tumors. As exemplified in our series, Gd enhancement on MR images was reliable neither for the distinction between neoplastic and nonneoplastic lesions, nor for the separation between low-grade (WHO Grade II) and high-grade (WHO Grades III and IV) gliomas. In our series, 100% of the GBMs Grade IV, 36% of the anaplastic Grade III gliomas, and 33% of the diffuse Grade II gliomas did demonstrate Gd enhancement. Therefore and in light of the known regional heterogeneity of gliomas, selection of biopsy sites based on MR imaging abnormalities alone carries the risk of taking tissue samples that either are diagnostically nonspecific or may not be representative of the entire lesion (for example, one may underestimate the true malignancy grade by missing the most malignant area).
Numerous attempts have been made to use PET scanning for the improvement of noninvasive diagnostic assessment and treatment planning of brain tumors. 14, 16, 18, 21, 25, 43, 44 The uptake of the most commonly used PET tracer, FDG, is related to the grade of gliomas. 23 Given that FDG uptake is low or absent in low-grade gliomas, however, this tracer is generally not helpful in the delineation of low-grade diffuse gliomas. 14 Other authors have tried to incorporate information provided by MET-PET into their treatment planning for gliomas after biopsy or subtotal resection. 43 Still, authors in another study found that target localization for tissue biopsies based on either MET-PET or FDG-PET was more successful in detecting diagnostically meaningful tumor tissue compared with anatomical imaging alone. 35 Note that FET is one of the first 18 F-labeled amino acids that can be produced in large quantities for clinical purposes and is applicable for PET studies in a satellite concept. 17, 60 With an effective dose of approximately 3 mSv, the burden of radiation is low 47 and the entire brain may be examined in approximately 20 minutes. The uptake of FET is mediated by specific amino acid transporters, but FET is not incorporated into proteins. 20, 31, 59 Transport experiments with FET in F98 rat glioma cells revealed a sodium-dependent transport via system B 0,+ in addition to sodium-independent transport via system L. Thus, the transport characteristics of FET in this cell line were similar to those of MET. 31 In the present study, the mean lesion/brain tissue ratio of FET uptake was significantly greater for gliomas than for nonneoplastic lesions. The sensitivity and specificity of the FET uptake for the distinction of neoplastic and nonneoplastic lesions were 88% and 88%, respectively. We found that a small percentage (11%) of the gliomas in our series did not accumulate FET. A similar percentage of gliomas without increased amino acid uptake has been reported for MET-PET scanning. 3, 6 In contrast to the findings with FDG-PET, 23 our data indicate that FET-PET is not helpful in predicting the WHO grade of gliomas.
Interestingly, the area of significant FET uptake was always smaller than and located within the area of MR signal abnormality in gliomas of WHO Grades I to III. This observation indicates that the extension of diagnostically meaningful tumor tissue is often overestimated by the signal abnormalities on MR images of WHO Grades I to III gliomas. In GBMs, however, the situation may be different. In our series, two of five patients with GBM demonstrated significant FET uptake expanding more than 10 mm over the outer border of the MR signal abnormality. Thus, the actual tumor extension may be underestimated by using MR imaging in such cases and is probably more precisely represented by FET-PET.
Magnetic resonance spectroscopy is a well-proven and well-established diagnostic tool in the evaluation of gliomas. We used MR spectroscopy with a single-voxel technique because it has several advantages that fit our study design and purpose. 1) Single-voxel MR spectroscopy leads to more stable results of signal intensity ratio values of the different metabolites. 2) In comparison to MR spectroscopic imaging, the local magnetic field homogeneity within the target volume of MR spectroscopy is better due to optimization to a smaller area within the tumor tissue, which leads to an improved quality of the spectra. 3) In MR spectroscopic imaging, the spatial resolution is poor and therefore the tumor spectra may not be localized as precisely as in single-voxel MR spectroscopy within the tumor tissue. In these cases with insufficient target volume localization, the spectra will be contaminated due to partial volume effects. In small lesions especially near the ventricle or in lesions near the skull bone, the placement of a small single voxel into the lesion provides more valid metabolic information than provided by MR spectroscopic imaging. Data obtained using the latter method can be contaminated by cerebrospinal fluid, air-filled spaces, bone marrow, or subcutaneous fat and therefore the data acquisition process can be disturbed when a small lesion is located near these structures. 48, 57 Furthermore MR spectroscopy is easy to perform and therefore available at more institutions. The relatively short period of time required for data acquisition makes it more accepted by both the patients and the MR unit personnel. These are essential criteria to bring metabolic imaging with MR spectroscopy into the routine setting of diagnostics in glioma. Disadvantages of single-voxel MR spectroscopy include the lack of information on the extent of the metabolic abnormalities in large tumors and the inaccuracy in defining the exact extent of tumor tissue and tissue heterogeneity within the tumor. Only recently, techniques have been applied that allowed 3D coverage of a lesion for retrospective correlation of metabolite levels and histological features. 11, 42 To date, however, 3D MR spectroscopy could not cover the entire brain with an acceptable resolution and within a reasonable amount of time. In addition, image registration of 3D MR spectroscopic data for neuronavigational or stereotactic biopsies is problematic.
The aforementioned disadvantages of MR spectroscopy and MR spectroscopic imaging are not apparent for PET scanning, an alternative technique to make visible metabolic information in gliomas. Positron emission tomography provides metabolic information about the entire brain in a relatively short time and can be used in image-guided biopsies. 34 When compared with FET-PET, MR spectroscopy turned out to be even more sensitive in the prediction of neoplastic intracerebral lesions. All 34 histologically proven gliomas in our series showed a positive result on MR spectroscopy studies (100% sensitivity) and the specificity was 81%. These results are comparable to those from other studies in which were reported sensitivities of 90 to 97% and specificities of 85 to 88% for the detection of gliomas. 10, 32, 38 Thus, MR spectroscopy may provide valuable additional information on intracerebral lesions that are not bona fide gliomas on CT scans and MR images. Because of its better availability, lower costs, and high sensitivity compared with FET-PET, MR spectroscopy represents the first method of choice in such instances. In case of a negative result on MR spectroscopy, the likelihood of a tumor diagnosis on stereotactic or neuronavigated biopsy procedures is close to 0%. In these patients, further metabolic imaging does not appear to be useful and MR imaging follow up at regular intervals may be sufficient, unless a treatable lesion (for example, a brain abscess) is suspected and histological confirmation is definitely required. In case of a positive MR spectroscopy result, further specification with FET-PET is advisable, in particular for large and/or multifocal lesions, to identify the best location for diagnostic tissue biopsy specimens.
Conclusions
In newly diagnosed cerebral lesions that are suspected of being diffuse gliomas based on MR imaging, biopsy site selection based solely on MR imaging carries a considerable risk of targeting areas that are diagnostically nonspecific or not representative of the entire lesion. The additional use of metabolic imaging-MR spectroscopy and FET-PETprovides important additional information that may help to decide whether and where a cerebral lesion should be sampled for biopsy. In cases of concordant results on both metabolic investigations, the predictive value is extremely high. We found that tissue biopsies never revealed a definite glioma diagnosis when MR spectroscopy and FET-PET results were both negative. In contrast, when results of both methods were positive, a definite glioma diagnosis could be histologically established in 97% of the cases. Based on our findings, we concluded that MR spectroscopy is very helpful in identifying brain lesions that are likely to result in a definite glioma diagnosis on targeted biopsies. In such cases, additional FET-PET studies may help to select the optimal biopsy site. In cases of a negative result on MR spectroscopy, one may consider postponing the biopsy procedure and instead following up the patient by performing imaging studies at regular intervals.
